Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Saxagliptin safety information

The manufacturer has written to healthcare professionals regarding new safety information for saxagliptin (Onglyza®).

The letter advises that saxagliptin has been associated with serious hypersensitivity reactions and acute pancreatitis. The following recommendations have now been made:

  • Saxagliptin is contraindicated in patients with a history of serious hypersensitivity reactions including anaphylactic reactions, anaphylactic shock and angioedema to saxagliptin or any other dipeptidyl peptidase 4 (DPP-4) inhibitor
  • Patients should be advised of the symptoms of acute pancreatitis and rapidly report such symptoms
  • Where hypersensitivity reactions or pancreatitis are suspected, saxagliptin should be discontinued

Action: Clinicians should be aware of this new safety information and implement any necessary changes to practice.

Share 'Saxagliptin safety information' on Email Share 'Saxagliptin safety information' on Delicious Share 'Saxagliptin safety information' on Digg Share 'Saxagliptin safety information' on Facebook Share 'Saxagliptin safety information' on Google+ Share 'Saxagliptin safety information' on reddit Share 'Saxagliptin safety information' on StumbleUpon Share 'Saxagliptin safety information' on Twitter

atomic-wealth

No Comments to “Saxagliptin safety information”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,665 spam comments.

atomic-wealth
fond-illness
summer